GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Enterprise Value

Leap Therapeutics (FRA:5MC) Enterprise Value : €48.31 Mil (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Leap Therapeutics's Enterprise Value is €48.31 Mil. Leap Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-58.92 Mil. Therefore, Leap Therapeutics's EV-to-EBIT ratio for today is -0.82.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Leap Therapeutics's Enterprise Value is €48.31 Mil. Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-58.91 Mil. Therefore, Leap Therapeutics's EV-to-EBITDA ratio for today is -0.82.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Leap Therapeutics's Enterprise Value is €48.31 Mil. Leap Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil. Therefore, Leap Therapeutics's EV-to-Revenue ratio for today is .


Leap Therapeutics Enterprise Value Historical Data

The historical data trend for Leap Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Enterprise Value Chart

Leap Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.83 59.07 131.87 -21.56 43.35

Leap Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.68 43.35 11.97 -12.77 32.51

Competitive Comparison of Leap Therapeutics's Enterprise Value

For the Biotechnology subindustry, Leap Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Leap Therapeutics's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's Enterprise Value falls into.



Leap Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Leap Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Leap Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Leap Therapeutics  (FRA:5MC) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Leap Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=48.306/-58.919
=-0.82

Leap Therapeutics's current Enterprise Value is €48.31 Mil.
Leap Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-58.92 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Leap Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=48.306/-58.91
=-0.82

Leap Therapeutics's current Enterprise Value is €48.31 Mil.
Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-58.91 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Leap Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=48.306/0
=

Leap Therapeutics's current Enterprise Value is €48.31 Mil.
Leap Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Leap Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Leap Therapeutics Business Description

Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Leap Therapeutics Headlines

No Headlines